Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Julphar
Fish and Richardson
Moodys
McKesson
Cantor Fitzgerald
Novartis
Johnson and Johnson
UBS
Dow

Generated: October 20, 2017

DrugPatentWatch Database Preview

ZYMAR Drug Profile

« Back to Dashboard

Which patents cover Zymar, and what generic Zymar alternatives are available?

Zymar is a drug marketed by Allergan and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has eighteen patent family members in fifteen countries and one supplementary protection certificate in one country.

The generic ingredient in ZYMAR is gatifloxacin. There are sixteen drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the gatifloxacin profile page.

Summary for Tradename: ZYMAR

US Patents:1
Applicants:1
NDAs:1
Bulk Api Vendors: see list81
Clinical Trials: see list9
Patent Applications: see list3,625
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ZYMAR at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan
ZYMAR
gatifloxacin
SOLUTION/DROPS;OPHTHALMIC021493-001Mar 28, 2003RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ZYMAR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan
ZYMAR
gatifloxacin
SOLUTION/DROPS;OPHTHALMIC021493-001Mar 28, 2003► Subscribe► Subscribe
Allergan
ZYMAR
gatifloxacin
SOLUTION/DROPS;OPHTHALMIC021493-001Mar 28, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for ZYMAR

Drugname Dosage Strength RLD Submissiondate
gatifloxacinOphthalmic Solution0.30%Zymar7/19/2007

International Patent Family for Tradename: ZYMAR

Country Document Number Estimated Expiration
Hong Kong1029934► Subscribe
China1133432► Subscribe
Denmark1025846► Subscribe
Australia761040► Subscribe
Canada2307632► Subscribe
Austria332692► Subscribe
World Intellectual Property Organization (WIPO)0010570► Subscribe
Spain2264266► Subscribe
Australia5302699► Subscribe
BrazilPI9906735► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ZYMAR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00110Netherlands► SubscribePRODUCT NAME: GATIFLOXACINUM, DESGEWENST IN DE VORM VAN EEN HYDRAAT, ZUURADDITIEZOUT OF ALKALISCH ZOUT, IN HET BIJZONDER GATIFLOXACINUM SESQUIHYDRICUM; REGISTRATION NO/DATE: DE 48870.00.00, 48870.01.00, 48872.00.00, 48872.01.00, 48874.00.00, 48874.01.00, 48876.00.00, 48876.01.00 20011022
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Daiichi Sankyo
Farmers Insurance
Deloitte
Accenture
Mallinckrodt
Citi
QuintilesIMS
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot